Skip to main content

Table 1 Selected patient and tumour characteristics.

From: A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study

  Total
N= 189
Group A (CP)
N= 96
Group B (CLD)
N= 93
Age (years)    
Median (range) 63 (37-89) 63 (37-81) 62 (38-89)
Performance status    
0 117 (62) 62 (65) 55 (59)
1 57 (30) 27 (28) 30 (32)
2 1 (1) 0 (0) 1 (1)
Unknown 14 (7) 7 (7) 7 (8)
Stage at diagnosis    
I 14 (7) 9 (9) 5 (5)
II 16 (9) 9 (9) 7 (8)
III 118 (62) 56 (58) 62 (67)
IV 28 (15) 15 (16) 13 (14)
Unknown 13 (7) 7 (7) 6 (7)
Histologic grade    
I 13 (7) 8 (8) 5 (5)
II 57 (30) 27 (28) 30 (32)
III 92 (49) 48 (50) 44 (47)
IV 3 (2) 1 (1) 2 (2)
Unknown 24 (13) 12 (13) 12 (13)
Histologic type    
Serous 143 (76) 71 (74) 72 (77)
Mucinous 3 (2) 0 (0) 3 (3)
Endometroid 13 (7) 6 (6) 7 (8)
Clear cell 6 (3) 3 (3) 3 (3)
Other 14 (7) 9 (9) 5 (5)
Unknown 10 (5) 7 (7) 3 (3)
Prior therapy    
Surgery 161 (85) 85 (89) 76 (82)
Taxane containing therapy 170 (90) 84 (88) 86 (93)
Number of prior chemotherapy lines    
1 181 (96) 92 (96) 89 (96)
> = 2 8 (4) 4 (4) 4 (4)
Sites of disease    
Abdominal 95 (50) 49 (51) 46 (50)
Abdominal and pleural effusion or ascites 43 (23) 18 (19) 25 (27)
Extra-abdominal 1 (1) 1 (1) 0 (0)
Both 9 (5) 5 (5) 4 (4)
Ascites or pleural effusion and elevated CA125 14 (7) 10 (10) 4 (4)
Elevated CA 125 as the only evidence of disease 16 (8) 7 (7) 9 (10)
Unknown 11 (6) 6 (6) 5 (5)
Platinum free interval    
6-12 months 54 (29) 32 (33) 22 (23)
12.1-24 months 70 (37) 32 (33) 38 (41)
> 24 months 52 (28) 23 (24) 29 (31)
Unknown 13 (7) 9 (9) 4 (4)
Median platinum-free interval (months) 16.5 (6-119) 14.8 (6-96) 17.3 (6-119)
CA 125 at baseline    
Median (range) 207 (4-6000) 210 (7-6000) 199 (4-3400)
  1. CP, carboplatin plus paclitaxel; CLD, carboplatin plus pegylated liposomal doxorubicin